Compare Gilead Sciences, Inc. (GILD) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wheaton Precious Metals Corp — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Wheaton Precious Metals Corp trades at $104.41 (market cap $48.80B). The key difference: Gilead Sciences, Inc. is far larger — about 3.4× Wheaton Precious Metals Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | WPM | |
|---|---|---|
Market Cap | $163.51B | $48.80B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $165.72 |
52-Week Low | $108.22 | $88.32 |
Enterprise Value | $178.05B | $46.65B |
Dividend Yield | 2.49% | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Wheaton Precious Metals (WPM) trades at $108.49, up 0.61% on the day, amid a bearish technical signal but strong fundamental performance. The company reported record operating cash flow of $1.9 billion in 2025, with revenue surging to $2.31 billion and net income reaching $1.47 billion. Recent quarterly earnings have consistently beaten expectations, and analyst consensus remains strongly bullish with an 80% buy rating and a $161.75 price target, suggesting significant upside from current levels.
The outlook for WPM is positive, driven by robust cash flow generation, production growth, and favorable precious metal exposure. Key risks include sensitivity to commodity price volatility and macroeconomic pressures. With a high valuation (P/E 27.43) but strong profitability (ROE 21.54%), the stock presents a growth opportunity tempered by market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
